From all around the world vets have met two weeks ago for the 3rd World Veterinary Cancer Congress in Foz do Iguazu/Brazil. We are proud, we had an inivation to present our clinical results of the immunologic treatment of dogs with splenic hemangiosarcoma stage II and III. We could show a median survial of 456 days and a mean survival of the patients of 701 days. Please find the presentation following this link: https://www.petbiocell.de/en/system/files/verwaltung/informationsportal/...

We recommend to start immediately post-surgery and a malign pathohistological diagnosis with the immunologic treatment. At this very early moment you have the chance to combine the massive cytoreduction of the tumor tissue with an immediate immune response. Because of the superior characteristics of the immune stimulation (no biohazard for vet team and owner, if at all, only minor side effects) you have a new opportunity to treat the animals in their familiar environment.

We are looking forward to provide you with further information via email or phone. Or we meet in Vienna at the FECAVA-conference next week (www.fecava2016.org). See or hear from you soon

Your PetBioCell Team